Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Net Margin (2018 - 2025)

Bicycle Therapeutics' Net Margin history spans 8 years, with the latest figure at 42.03% for Q4 2025.

  • For Q4 2025, Net Margin rose 135641.0% year-over-year to 42.03%; the TTM value through Dec 2025 reached 301.66%, up 34486.0%, while the annual FY2025 figure was 301.66%, 17752.0% up from the prior year.
  • Net Margin reached 42.03% in Q4 2025 per BCYC's latest filing, up from 503.66% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 42.03% in Q4 2025 to a low of 2703.84% in Q2 2025.
  • Average Net Margin over 5 years is 827.45%, with a median of 755.98% recorded in 2022.
  • The largest YoY upside for Net Margin was 139477bps in 2025 against a maximum downside of -227854bps in 2025.
  • A 5-year view of Net Margin shows it stood at 1127.31% in 2021, then soared by 68bps to 356.88% in 2022, then crashed by -158bps to 921.01% in 2023, then tumbled by -52bps to 1398.44% in 2024, then skyrocketed by 97bps to 42.03% in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Net Margin are 42.03% (Q4 2025), 503.66% (Q3 2025), and 2703.84% (Q2 2025).